Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone646-350-0702
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees17
Next Earnings Date11/21/2019 (Estimated)
OptionableNot Optionable
Akari Therapeutics (NASDAQ:AKTX) Frequently Asked Questions
What is Akari Therapeutics' stock symbol?
Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."
How were Akari Therapeutics' earnings last quarter?
Akari Therapeutics PLC (NASDAQ:AKTX) issued its quarterly earnings results on Thursday, August, 29th. The biopharmaceutical company reported ($0.26) EPS for the quarter. View Akari Therapeutics' Earnings History.
When is Akari Therapeutics' next earnings date?
What price target have analysts set for AKTX?
1 brokers have issued 12-month price objectives for Akari Therapeutics' shares. Their forecasts range from $7.00 to $7.00. On average, they expect Akari Therapeutics' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 311.8% from the stock's current price. View Analyst Price Targets for Akari Therapeutics.
What is the consensus analysts' recommendation for Akari Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akari Therapeutics.
Has Akari Therapeutics been receiving favorable news coverage?
News stories about AKTX stock have trended negative recently, InfoTrie reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Akari Therapeutics earned a news sentiment score of -2.5 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Akari Therapeutics.
Are investors shorting Akari Therapeutics?
Akari Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 583,000 shares, an increase of 176.8% from the August 30th total of 210,600 shares. Based on an average daily trading volume, of 1,090,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 3.3% of the shares of the company are sold short. View Akari Therapeutics' Current Options Chain.
Who are some of Akari Therapeutics' key competitors?
Some companies that are related to Akari Therapeutics include Helix Biopharma (HBPCF), Strongbridge Biopharma (SBBP), Paratek Pharmaceuticals (PRTK), Fulcrum Therapeutics (FULC), Eton Pharmaceuticals (ETON), Corvus Pharmaceuticals (CRVS), Correvio Pharma (CORV), Aptinyx (APTX), Chembio Diagnostics (CEMI), Processa Pharmaceuticals (PCSA), Avenue Therapeutics (ATXI), VBI Vaccines (VBIV), Millendo Therapeutics (MLND), CELYAD SA/ADR (CYAD) and Fortress Biotech (FBIO).
What other stocks do shareholders of Akari Therapeutics own?
Who are Akari Therapeutics' key executives?
Akari Therapeutics' management team includes the folowing people:
- Dr. Ray Prudo, Exec. Chairman (Age 74)
- Mr. Clive Richardson, COO, Director & Interim CEO (Age 54)
- Mr. Dov Elefant, Chief Financial Officer (Age 52)
- Dr. Miles Nunn, Chief Scientific Officer
How do I buy shares of Akari Therapeutics?
Shares of AKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Akari Therapeutics' stock price today?
One share of AKTX stock can currently be purchased for approximately $1.70.
How big of a company is Akari Therapeutics?
Akari Therapeutics has a market capitalization of $26.96 million. The biopharmaceutical company earns $-16,470,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Akari Therapeutics employs 17 workers across the globe.View Additional Information About Akari Therapeutics.
What is Akari Therapeutics' official website?
How can I contact Akari Therapeutics?
Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The biopharmaceutical company can be reached via phone at 646-350-0702 or via email at [email protected]
MarketBeat Community Rating for Akari Therapeutics (NASDAQ AKTX)
MarketBeat's community ratings are surveys of what our community members think about Akari Therapeutics and other stocks. Vote "Outperform" if you believe AKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
